Source comparison
CJC-1295 Ipamorelin for Skin Elasticity: Peptide Comparison
CJC-1295 (with DAC) GHRH analog. Extends endogenous GH pulse duration via albumin binding 6–8 days 1–2× weekly Baseline elevation. Minimal without pulse component Provides foundation but requires pulse trigger for dermal remodeling Ipamorelin Selective ghrelin
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- GHRH analog. Extends endogenous GH pulse duration via albumin binding
- 6–8 days
- 1–2× weekly
- Baseline elevation. Minimal without pulse component
- Provides foundation but requires pulse trigger for dermal remodeling
- Ipamorelin
- Selective ghrelin receptor agonist. Triggers acute GH pulse without cortisol elevation
- 2 hours
- 1–2× daily
- Pulsatile signaling. Effective only with sustained baseline
- Delivers rhythm but needs baseline support for fibroblast activation
- CJC-1295 + Ipamorelin
- Dual pathway: sustained baseline + timed pulses
- Combined
- CJC 1–2×/week + Ipamorelin daily
- 18–22% increase in ultrasound-measured dermal thickness
- Gold standard for peptide-based skin elasticity protocols. Synergistic outcome
- GHK-Cu (Copper Peptide)
- TGF-beta stimulation, metalloproteinase modulation
- Hours (topical)
- Daily topical application
- 8–12% improvement in elasticity scores
- Effective for surface remodeling but cannot match systemic GH-driven collagen synthesis
- Matrixyl (Palmitoyl Pentapeptide)
- Procollagen gene expression via fibroblast signaling
- N/A (topical)
- Twice daily topical
- 5–9% improvement in clinical elasticity measurement
- Works through direct fibroblast contact. Limited by dermal penetration depth